514 related articles for article (PubMed ID: 11597033)
21. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
[TBL] [Abstract][Full Text] [Related]
22. Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy.
Bergstein J; Leiser J; Andreoli SP
Clin Nephrol; 1998 Jan; 49(1):9-14. PubMed ID: 9491279
[TBL] [Abstract][Full Text] [Related]
23. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy.
Roccatello D; Ferro M; Coppo R; Giraudo G; Quattrocchio G; Piccoli G
Nephrol Dial Transplant; 1995 Nov; 10(11):2054-9. PubMed ID: 8643167
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
25. Corticosteroid therapy in patients with IgA nephropathy and impaired renal function.
Tamura S; Ueki K; Ideura H; Tsukada Y; Maezawa A; Kawai H; Wakamatsu R; Yano S; Nojima Y; Naruse T
Clin Nephrol; 2001 Mar; 55(3):192-5. PubMed ID: 11316238
[TBL] [Abstract][Full Text] [Related]
26. [Effects of steroid therapy in IgA nephropathy].
Ohashi T; Shimokawahara H; Fukumoto M; Azuma K; Uchida Y; Tokuda Y; Ito H; Yasumoto Y; Yamashita W; Harada R
Fukuoka Igaku Zasshi; 1992 May; 83(5):209-15. PubMed ID: 1612550
[TBL] [Abstract][Full Text] [Related]
27. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases.
Kobayashi Y; Fujii K; Hiki Y; Tateno S
Q J Med; 1986 Oct; 61(234):935-43. PubMed ID: 3628707
[TBL] [Abstract][Full Text] [Related]
28. [Long-term administration of cyclosporine A in patients with IgA nephropathy].
Chábová V; Tesar V; Zabka J; Rychlík I; Merta M; Jirsa M; Stejskalová A; Stejskal J
Cas Lek Cesk; 1996 Dec; 135(24):803-6. PubMed ID: 9072300
[TBL] [Abstract][Full Text] [Related]
29. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial.
Walker RG; Yu SH; Owen JE; Kincaid-Smith P
Clin Nephrol; 1990 Sep; 34(3):103-7. PubMed ID: 2225560
[TBL] [Abstract][Full Text] [Related]
30. Regression of IgA nephropathy: a repeat biopsy study.
Hotta O; Furuta T; Chiba S; Tomioka S; Taguma Y
Am J Kidney Dis; 2002 Mar; 39(3):493-502. PubMed ID: 11877568
[TBL] [Abstract][Full Text] [Related]
31. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial.
Kanno Y; Witt M; Okada H; Nemoto H; Sugahara S; Nakamoto H; Suzuki H
Clin Exp Nephrol; 2003 Mar; 7(1):48-51. PubMed ID: 14586743
[TBL] [Abstract][Full Text] [Related]
32. [Steroid-responsive nephrotic syndrome in IgA nephropathy].
García Camín RM; Cabezas A; Calero F; Ballarín JA
Nefrologia; 2004; 24 Suppl 3():68-71. PubMed ID: 15219073
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
34. Henoch-Schönlein purpura nephritis with nephrotic-range proteinuria: histological regression possibly associated with cyclosporin A and steroid treatment.
Shin JI; Park JM; Shin YH; Kim JH; Lee JS; Jeong HJ
Scand J Rheumatol; 2005; 34(5):392-5. PubMed ID: 16234188
[TBL] [Abstract][Full Text] [Related]
35. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands.
Hofstra JM; Wetzels JF
Nephrol Dial Transplant; 2008 Nov; 23(11):3534-8. PubMed ID: 18559961
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation of tonsillectomy with modified high-dose intravenous methylprednisolone therapy in patients with IgA nephropathy].
Sugawara K; Takeda K; Nakai K; Takahashi N; Adachi T; Fukuda T; Miura S
Nihon Jinzo Gakkai Shi; 2008; 50(8):1017-23. PubMed ID: 19172803
[TBL] [Abstract][Full Text] [Related]
37. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
Parinyasiri U; Ong-Ajyooth L; Parichatikanond P; Ong-Ajyooth S; Liammongkolkul S; Kanyog S
J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
[TBL] [Abstract][Full Text] [Related]
38. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study.
Manno C; Strippoli GF; D'Altri C; Torres D; Rossini M; Schena FP
Am J Kidney Dis; 2007 Jun; 49(6):763-75. PubMed ID: 17533019
[TBL] [Abstract][Full Text] [Related]
39. Effects of methylprednisolone and cyclophosphamide pulse therapy on renal infiltrating cells in patients with crescentic glomerulonephritis.
Tang Z; Zhou H; Yao X; Hu W; Leishi L
Chin Med J (Engl); 1997 Mar; 110(3):206-9. PubMed ID: 9594342
[TBL] [Abstract][Full Text] [Related]
40. Recurrence of IgA nephropathy with crescents in kidney transplants.
Mousson C; Charon-Barra C; Funes de la Vega M; Tanter Y; Justrabo E; Martin L; Rifle G
Transplant Proc; 2007 Oct; 39(8):2595-6. PubMed ID: 17954186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
